$APYP
APPYEA, INC Stock $apyp

$apyp Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031777 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$430.0K	$514.0K
YoY Change
% of Gross Profit
Research & Development	$60.00K	$31.00K
YoY Change		675.0%
% of Gross Profit
Depreciation & Amortization	$0.00	$10.00K	$20.00K
YoY Change	-100.0%
% of Gross Profit
Operating Expenses	$490.0K	$545.0K
YoY Change		13525.0%
Operating Profit		-$545.0K
YoY Change		240.63%
Interest Expense	$10.00K	-$20.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$90.00K	-$19.00K
YoY Change
Pretax Income	-$570.0K	-$683.0K
YoY Change		324.22%
Income Tax
% Of Pretax Income
Net Earnings	-$570.0K	-$683.0K
YoY Change		324.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00
COMMON SHARES
Basic Shares Outstanding	220.9M shares	220.7M shares
Diluted Shares Outstanding		220.7B shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$60.00K	$80.00K
YoY Change
Cash & Equivalents	$60.00K	$82.00K	$206.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$20.00K	$20.00K
Other Receivables	$19.00K	$22.00K	$13.00K
Total Short-Term Assets	$79.00K	$104.0K	$356.0K
YoY Change	-77.81%		3460.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.000K	$2.000K	$2.000K
YoY Change	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$126.0K	$132.0K	$150.0K
YoY Change	-16.0%
TOTAL ASSETS
Total Short-Term Assets	$79.00K	$104.0K	$356.0K
Total Long-Term Assets	$126.0K	$132.0K	$150.0K
Total Assets	$205.0K	$236.0K	$506.0K
YoY Change	-59.49%		4960.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$70.00K	$50.00K
YoY Change
Accrued Expenses	$62.00K	$200.0K	$13.00K
YoY Change	376.92%
Deferred Revenue
YoY Change
Short-Term Debt	$693.0K	$559.0K	$112.0K
YoY Change	518.75%		180.0%
Long-Term Debt Due	$1.530M	$1.470M
YoY Change
Total Short-Term Liabilities	$2.768M	$2.514M	$2.521M
YoY Change	9.8%		4942.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities			$415.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.768M	$2.514M	$2.521M
Total Long-Term Liabilities			$415.0K
Total Liabilities	$2.768M	$2.514M	$2.936M
YoY Change	-5.72%		7240.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.509M	-$3.943M	-$3.205M
YoY Change	40.69%
Common Stock	$21.00K	$21.00K	$21.00K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.549M	-$2.264M	-$2.416M
YoY Change
Total Liabilities & Shareholders Equity	$205.0K	$236.0K	$506.0K
YoY Change	-59.49%		4960.0%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	-$570.0K	-$683.0K
YoY Change		324.22%
Depreciation, Depletion And Amortization	$0.00	$10.00K	$20.00K
YoY Change	-100.0%
Cash From Operating Activities	-$90.00K	-$110.0K	-$80.00K
YoY Change	12.5%		-300.0%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$170.0K
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$0.00	$170.0K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	50.00K	0.000	70.00K
YoY Change	-28.57%		600.0%
NET CHANGE
Cash From Operating Activities	-90.00K	-110.0K	-80.00K
Cash From Investing Activities	0.000	0.000	170.0K
Cash From Financing Activities	50.00K	0.000	70.00K
Net Change In Cash	-40.00K	-110.0K	160.0K
YoY Change	-125.0%		220.0%
FREE CASH FLOW
Cash From Operating Activities	-$90.00K	-$110.0K	-$80.00K
Capital Expenditures			$0.00
Free Cash Flow			-$80.00K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001568969
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent		usd
CY2022Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2021Q4	APYP	Shares To Be Issued SharesToBeIssued		usd
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense		usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense		usd
CY2021Q3	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability		usd
	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability		usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	APYP	Issuance Of Warrants Measured At Fv IssuanceOfWarrantsMeasuredAtFv		usd
CY2022Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent		usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent		usd
	us-gaap	Management Fee Expense ManagementFeeExpense		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-264834
	dei	Entity Registrant Name EntityRegistrantName	APPYEA, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1496846
	dei	Entity Address Address Line1 EntityAddressAddressLine1	16 Natan Alterman St
	dei	Entity Address City Or Town EntityAddressCityOrTown	Gan Yavne
	dei	Entity Address Country EntityAddressCountry	IL
	dei	City Area Code CityAreaCode	(800)
	dei	Local Phone Number LocalPhoneNumber	674-3561
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	220930798	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	206000	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	22000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	13000	usd
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	137000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	104000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	356000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	130000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	148000	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	132000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	150000	usd
CY2022Q3	us-gaap	Assets Assets	236000	usd
CY2021Q4	us-gaap	Assets Assets	506000	usd
CY2022Q3	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	50000	usd
CY2021Q4	us-gaap	Interest And Dividends Payable Current InterestAndDividendsPayableCurrent	30000	usd
CY2022Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	195000	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	65000	usd
CY2022Q3	APYP	Short Term Loans From Related Party ShortTermLoansFromRelatedParty	89000	usd
CY2021Q4	APYP	Short Term Loans From Related Party ShortTermLoansFromRelatedParty	89000	usd
CY2022Q3	APYP	Short Term Convertible Loans Related Party ShortTermConvertibleLoansRelatedParty	28000	usd
CY2021Q4	APYP	Short Term Convertible Loans Related Party ShortTermConvertibleLoansRelatedParty	32000	usd
CY2022Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	559000	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	112000	usd
CY2022Q3	APYP	Short Term Convertible Loans ShortTermConvertibleLoans	1465000	usd
CY2021Q4	APYP	Short Term Convertible Loans ShortTermConvertibleLoans	1933000	usd
CY2022Q3	APYP	Short Term Warrants Liability ShortTermWarrantsLiability	128000	usd
CY2021Q4	APYP	Short Term Warrants Liability ShortTermWarrantsLiability	260000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2514000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2521000	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	415000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	415000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2514000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2936000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	21000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	21000	usd
CY2022Q3	APYP	Shares To Be Issued SharesToBeIssued	22000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1636000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	768000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3943000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3205000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2264000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2416000	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	-14000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-14000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2278000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2430000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	236000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	506000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	513000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	156000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1592000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	186000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-545000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-160000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1677000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-256000	usd
CY2022Q3	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	119000	usd
	APYP	Change In Fair Value Of Convertible Loans And Warrant Liability ChangeInFairValueOfConvertibleLoansAndWarrantLiability	-1004000	usd
CY2022Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	19000	usd
CY2021Q3	us-gaap	Interest And Debt Expense InterestAndDebtExpense	1000	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	65000	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-683000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-161000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-738000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-258000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-683000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-161000	usd
	us-gaap	Profit Loss ProfitLoss	-738000	usd
	us-gaap	Profit Loss ProfitLoss	-258000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-683000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-161000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-738000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-258000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	220730798	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130885410	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	219350536	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111253143	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2430000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	80000	usd
	APYP	Number Of Shares To Be Issued NumberOfSharesToBeIssued	35000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	775000	usd
	us-gaap	Profit Loss ProfitLoss	-738000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2278000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-37000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	299000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	92000	usd
	us-gaap	Profit Loss ProfitLoss	-258000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	98000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1869000	usd
CY2022Q3	APYP	Number Of Shares To Be Issued NumberOfSharesToBeIssued	7000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	267000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-683000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2278000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	165000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	165000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	92000	usd
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-161000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	98000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	98000	usd
	us-gaap	Profit Loss ProfitLoss	-738000	usd
	us-gaap	Profit Loss ProfitLoss	-258000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	877000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	92000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-939000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	9000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3000	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	195000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	91000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	41000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-505000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-118000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	131000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	368000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	61000	usd
	APYP	Issuance Of Warrants Measured At Fv IssuanceOfWarrantsMeasuredAtFv	9000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	390000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	192000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-9000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-124000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	75000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	206000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	82000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_zhQezSRoHM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_82A_ztvwg2Ao5MS">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AppYea, Inc. (“AppYea”, “the Company”, “we” or “us”) was incorporated in the State of South Dakota on November 26, 2012 to engage in the acquisition, purchase, maintenance and creation of mobile software applications. The Company is in the development stage with no significant revenues and no operating history. On November 1, 2021 the Company was redomiciled in the State of Nevada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s common stock is traded on the OTC Markets, under the symbol “APYP”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 22, 2022, the Company filed an application to the OTC Markets Group for being listed on the OTCQB tier. On October 14, 2022, the Company shares started trading on the OTCQB.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse merger</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In anticipation of the reverse merger described below, on July 2, 2021, Boris Molchadsky a majority shareholder of the Company, acquired in a private transaction from the former majority shareholder two hundred and twenty-five thousand (<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210702__20210702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--TitleOfIndividualAxis__custom--BorisMolchadskyMember_znW0QQ4T0a1k" title="Number of shares acquired">225,000</span>) Shares of Series A Preferred Stock of the Company. <span id="xdx_90B_eus-gaap--PreferredStockVotingRights_c20210702__20210702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--TitleOfIndividualAxis__custom--BorisMolchadskyMember_z3ydBd6ZsBr5" title="Preferred stock voting rights">The Series A Preferred Shares have the right to vote at 1,000 to 1 as shares of common stock and are convertible at a rate of 1,500 to 1 as shares of common stock of the Company</span>. The acquisition of the Preferred Shares provided Boris Molchadsky control of majority of the Company’s voting equity capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 2, 2021, the Company entered into a stock exchange agreement with SleepX Ltd., a company formed under the laws of the State of Israel (“SleepX”) and controlled by the majority shareholder of AppYea, Pursuant to the agreement, the outstanding equity capital consisting of <span id="xdx_90C_eus-gaap--SharesOutstanding_iI_pid_c20210802__us-gaap--TypeOfArrangementAxis__custom--StockExchangeAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zg2ugqxgtyB8" title="Outstanding equity capital">1,724</span> common shares of SleepX was exchanged for <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20210801__20210802__us-gaap--TypeOfArrangementAxis__custom--StockExchangeAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zwKD278zjzCf" title="Number shares exchanged for common stock">174,595,634</span> shares of common stock of the Company, based on the agreement that determined that to SleepX shareholders will be issued common shares in the amount that will result in them holding <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_c20210802__us-gaap--TypeOfArrangementAxis__custom--StockExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SleepXLtdMember_zVLWKwBIhJJa" title="Equity ownership percentage">80%</span> of the common shares issued of AppYea. As a result, SleepX became a wholly owned subsidiary of the Company. On December 31, 2021, the terms of the agreement were fulfilled; however, the issuance of the shares to SleepX shareholders, due to administrative matters, was completed in March 2022 after the Company completed a reverse stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the result of the transactions mentioned above, Mr. Molchadsky controls approximately <span id="xdx_906_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220930__srt--TitleOfIndividualAxis__custom--BorisMolchadskyMember__us-gaap--BusinessAcquisitionAxis__custom--AppYeaMember_zYv3FFe76Ujb" title="Voting interest rate">74%</span> of the total voting power of AppYea.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SleepX is an Israeli research and development company that has developed a unique product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and, subject to raising working capital, of which no assurance can be provided, the Company plans to start serial production in 2022. The Company will focus on further development and commercialization of the products. Its strategy will include continued investment in research and development and new initiatives in sales and marketing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SleepX has incorporated, together with an unrelated third party, a privately held company under the laws of the State of Israel named Ta-nooma Ltd. (“Ta-nooma”). Ta-nooma has developed sleeping monitoring technology for which patent applications were filed and has no revenue from operation. Since its incorporation and as of the financial statements date, SleepX holds <span id="xdx_908_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220930__us-gaap--BusinessAcquisitionAxis__custom--SleepXLtdMember_zVFryfSqSoNd" title="Voting interest rate">73.8%</span> of the voting interest of Ta-nooma.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to SleepX, the Company has four wholly owned subsidiaries with no active operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>APPYEA INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO THE FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - GENERAL (cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting treatment of Acquisition</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AppYea did not have an operation as of the date of the transactions and the Acquisition was accounted for as a reverse merger. The entity that issues securities (the legal acquirer or-AppYea) is identified as the acquiree for accounting purposes. The entity whose interests are acquired (SleepX.) is the acquirer for accounting purposes. Since SleepX is considered the accounting acquirer, these consolidated financial statements are prepared as a continuation of the operations of SleepX, except for the legal capital which is of AppYea.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The legal capital of AppYea in the financial statements is restated using the exchange ratio established in the stock exchange agreement to reflect the number of shares of the legal acquirer issued in the reverse merger.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial position</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements are presented on a going concern basis. The Company has not yet generated any material revenues, has suffered recurring losses from operations and is dependent upon external sources for financing its operations. As of September 30, 2022, and December 31, 2021, the Company has an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20220930_zyH5SAvsio2d" title="Accumulated deficit">3,943,000</span> and $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20211231_zBFI3XSJuIEb" title="Accumulated deficit">3,205,000</span>, respectively. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The Company intends to continue to finance its operating activities by raising capital. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms or at all. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may be required to implement cost reduction measures and may be required to delay part of its development programs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments for the values of assets and liabilities and their classification that may be necessary in the event that the Company is no longer able to continue its operations as a “going concern”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3943000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3205000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zjb1qOBjBkz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zMbdmMnRfuj">Use of Estimates in Preparation of Financial Statements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP accounting principles requires management to make estimates and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p>
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	137000	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	58000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	83000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	46000	usd
CY2022Q3	APYP	Short Term Loans From Related Party ShortTermLoansFromRelatedParty	89000	usd
CY2021Q4	APYP	Short Term Loans From Related Party ShortTermLoansFromRelatedParty	89000	usd
CY2022Q3	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	27000	usd
CY2021Q4	APYP	Convertible Loans Related Party Current ConvertibleLoansRelatedPartyCurrent	32000	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	264000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	743000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	743000000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	896000	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	135000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding Measurement Input WarrantsAndRightsOutstandingMeasurementInput	0.000611	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	491200000	shares
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	22000000	usd

Files In Submission

Name	View Source	Status
0001493152-22-031777-index-headers.html	Edgar Link	pending
0001493152-22-031777-index.html	Edgar Link	pending
0001493152-22-031777.txt	Edgar Link	pending
0001493152-22-031777-xbrl.zip	Edgar Link	pending
apyp-20220930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
apyp-20220930_pre.xml	Edgar Link	unprocessable
apyp-20220930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
apyp-20220930_def.xml	Edgar Link	unprocessable
apyp-20220930_cal.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYP
APPYEA, INC Stock $apyp

2022 Q4 Form 10-Q Financial Statement

#000149315222031777 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYP APPYEA, INC Stock $apyp

2022 Q4 Form 10-Q Financial Statement

#000149315222031777 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYP
APPYEA, INC Stock $apyp